NO325823B1 - Humaniserte antistoffer, fremgangsmate for a fremstille humaniserte antistoffer og anvendelsen av slike. - Google Patents
Humaniserte antistoffer, fremgangsmate for a fremstille humaniserte antistoffer og anvendelsen av slike. Download PDFInfo
- Publication number
- NO325823B1 NO325823B1 NO19994870A NO994870A NO325823B1 NO 325823 B1 NO325823 B1 NO 325823B1 NO 19994870 A NO19994870 A NO 19994870A NO 994870 A NO994870 A NO 994870A NO 325823 B1 NO325823 B1 NO 325823B1
- Authority
- NO
- Norway
- Prior art keywords
- domain
- seq
- substituted
- sequence shown
- residues
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 49
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 32
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 32
- 230000004614 tumor growth Effects 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 32
- 235000001014 amino acid Nutrition 0.000 claims description 26
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 25
- 239000004474 valine Substances 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 21
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 230000002137 anti-vascular effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 11
- 239000004472 Lysine Substances 0.000 claims 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 10
- 229960000310 isoleucine Drugs 0.000 claims 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 8
- 239000004473 Threonine Substances 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 6
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000012512 characterization method Methods 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 42
- 108091007433 antigens Proteins 0.000 description 42
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 22
- 241001529936 Murinae Species 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 108060003951 Immunoglobulin Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 102000018358 immunoglobulin Human genes 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 14
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 14
- 230000035772 mutation Effects 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 229940072221 immunoglobulins Drugs 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 238000002741 site-directed mutagenesis Methods 0.000 description 8
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 101710083689 Probable capsid protein Proteins 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 241000894007 species Species 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
- 229960003669 carbenicillin Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 150000007649 L alpha amino acids Chemical class 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000002556 adrenal cortex cell Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steering Control In Accordance With Driving Conditions (AREA)
- Semiconductor Lasers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83350497A | 1997-04-07 | 1997-04-07 | |
PCT/US1998/006724 WO1998045332A2 (en) | 1997-04-07 | 1998-04-03 | Humanized antibodies and methods for forming humanized antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
NO994870D0 NO994870D0 (no) | 1999-10-06 |
NO994870L NO994870L (no) | 1999-12-06 |
NO325823B1 true NO325823B1 (no) | 2008-07-21 |
Family
ID=25264594
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19994870A NO325823B1 (no) | 1997-04-07 | 1999-10-06 | Humaniserte antistoffer, fremgangsmate for a fremstille humaniserte antistoffer og anvendelsen av slike. |
NO2017039C NO2017039I2 (no) | 1997-04-07 | 2017-08-01 | Bevacizumab - forlenget SPC |
NO2019045C NO2019045I1 (no) | 1997-04-07 | 2019-12-11 | Ranibizumab - Forlenget SPC |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2017039C NO2017039I2 (no) | 1997-04-07 | 2017-08-01 | Bevacizumab - forlenget SPC |
NO2019045C NO2019045I1 (no) | 1997-04-07 | 2019-12-11 | Ranibizumab - Forlenget SPC |
Country Status (22)
Country | Link |
---|---|
EP (6) | EP0971959B1 (xx) |
JP (1) | JP4191258B2 (xx) |
KR (2) | KR100794454B1 (xx) |
CN (6) | CN101838328A (xx) |
AT (4) | ATE314395T1 (xx) |
AU (1) | AU740738B2 (xx) |
BR (1) | BRPI9809388B8 (xx) |
CA (1) | CA2286397C (xx) |
CY (3) | CY1111345T1 (xx) |
DE (3) | DE69832970T2 (xx) |
DK (4) | DK0971959T3 (xx) |
ES (4) | ES2349559T3 (xx) |
HK (7) | HK1025338A1 (xx) |
IL (3) | IL132239A0 (xx) |
LT (1) | LTC0973804I2 (xx) |
NO (3) | NO325823B1 (xx) |
NZ (1) | NZ500077A (xx) |
PT (5) | PT971959E (xx) |
SI (5) | SI1695985T1 (xx) |
TR (1) | TR199902818T2 (xx) |
WO (1) | WO1998045332A2 (xx) |
ZA (2) | ZA982907B (xx) |
Families Citing this family (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
EP0971959B1 (en) * | 1997-04-07 | 2005-12-28 | Genentech, Inc. | Humanized antibodies and methods for forming humanized antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
DE69939374D1 (de) | 1998-03-17 | 2008-10-02 | Genentech Inc | Zu vegf und bmp1 homologe polypeptide |
JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
JP4926320B2 (ja) | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US6346249B1 (en) * | 1999-10-22 | 2002-02-12 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products |
AU4884001A (en) | 2000-04-21 | 2001-11-07 | Fuso Pharmaceutical Ind | Novel collectins |
EP2275549A1 (en) | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
CA2648051A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
MXPA04007583A (es) * | 2002-02-11 | 2005-04-25 | Genentech Inc | Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno. |
EP1551453A4 (en) | 2002-06-17 | 2007-04-25 | Us Gov Health & Human Serv | SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME |
CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
NZ621449A (en) | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
CA2537055A1 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
CA2549594A1 (fr) | 2003-12-02 | 2005-06-23 | Institut Pasteur | Nouvelle souche de coronavirus associe au sras et ses applications |
EP2168986A3 (en) | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
EP1771474B1 (en) | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
EP2319492A3 (en) | 2004-10-21 | 2011-08-10 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
UA96139C2 (xx) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1)$антитело к нейропилину-1 (nrp1) |
EP2402373B1 (en) | 2006-01-05 | 2016-10-19 | Genentech, Inc. | Anti-EphB4 Antibodies and Methods Using Same |
WO2007127506A2 (en) | 2006-01-20 | 2007-11-08 | Genentech, Inc. | Anti-ephrinb2 antibodies and methods using same |
AR059851A1 (es) | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
KR101416078B1 (ko) * | 2006-05-25 | 2014-07-07 | 글락소 그룹 리미티드 | 변형된 인간화 항인터루킨18 항체 |
WO2008060705A2 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
CN1903880B (zh) * | 2006-08-02 | 2010-05-12 | 中国人民解放军军事医学科学院基础医学研究所 | 抗肿瘤血管内皮生长因子vegf-e抗原及其编码基因与应用 |
AR062419A1 (es) | 2006-08-21 | 2008-11-05 | Hoffmann La Roche | Terapia tumoral con un anticuerpo anti- vegf |
CN101148474B (zh) * | 2006-09-21 | 2014-06-11 | 上海杰隆生物工程股份有限公司 | 人源人血管内皮生长因子单克隆抗体及其制备方法 |
ES2582656T3 (es) | 2006-12-19 | 2016-09-14 | Genentech, Inc. | Antagonistas específicos del VEGF para terapia adyuvante y neoadyuvante, y el tratamiento de tumores en fase temprana |
JP2010530359A (ja) | 2007-05-17 | 2010-09-09 | ジェネンテック, インコーポレイテッド | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
CA2687247A1 (en) | 2007-05-17 | 2008-11-27 | Genentech, Inc. | Inhibition of tumor metastasis by anti neuropilin 2 antibodies |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
PL2840090T3 (pl) | 2007-10-30 | 2018-07-31 | Genentech, Inc. | Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej |
TW200924796A (en) | 2007-11-09 | 2009-06-16 | Genentech Inc | Activin receptor-like kinase-1 compositions and methods of use |
TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-vegf抗體 |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
CA3020290A1 (en) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
AR073829A1 (es) | 2008-10-14 | 2010-12-01 | Genentech Inc | Variantes de inmunoglobulinas y sus usos. |
RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
EP2361085B9 (en) | 2008-11-22 | 2019-01-02 | F.Hoffmann-La Roche Ag | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
WO2010075420A1 (en) | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
WO2010112193A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
EP2427496A4 (en) * | 2009-04-03 | 2013-05-15 | Vegenics Pty Ltd | ANTI-VEGF-D ANTIBODIES |
PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
TWI428142B (zh) | 2009-05-08 | 2014-03-01 | Genentech Inc | 人類化之抗-egfl7抗體及其使用方法 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US9079953B2 (en) * | 2009-06-17 | 2015-07-14 | Abbvie Biotherapeutics Inc. | Anti-VEGF antibodies and their uses |
KR20120106935A (ko) | 2009-07-13 | 2012-09-27 | 제넨테크, 인크. | 암의 치료를 위한 진단 방법 및 조성물 |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
CN102498129B (zh) | 2009-07-31 | 2016-03-02 | 霍夫曼-拉罗奇有限公司 | 使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移 |
SG178419A1 (en) | 2009-08-15 | 2012-04-27 | Genentech Inc | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
CN102597776A (zh) | 2009-09-11 | 2012-07-18 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌剂的可能性升高的患者的方法 |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
EP2478114B1 (en) | 2009-09-17 | 2014-12-17 | F.Hoffmann-La Roche Ag | Diagnostic methods for lung cancer |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
CN102051396B (zh) * | 2009-11-04 | 2014-07-16 | 无锡天演生物技术有限公司 | 雁阵式定域随机突变方法及其在单抗分子进化技术中的应用 |
EP2509626B1 (en) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c antibodies and methods using same |
TWI623323B (zh) | 2009-12-21 | 2018-05-11 | 建南德克公司 | 抗體調配物 |
WO2011079185A1 (en) | 2009-12-23 | 2011-06-30 | Genentech, Inc. | Anti-bv8 antibodies and uses thereof |
FR2955773B1 (fr) | 2010-02-01 | 2017-05-26 | Commissariat A L'energie Atomique | Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination |
EP3064509A3 (en) | 2010-02-23 | 2016-11-02 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of ovarian cancer |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
CN102863533B (zh) * | 2010-06-21 | 2013-12-11 | 中国科学技术大学 | 抗体人源化改造方法 |
CA2803792A1 (en) | 2010-07-09 | 2012-01-12 | Genentech, Inc. | Anti-neuropilin antibodies and methods of use |
MX2013000667A (es) | 2010-07-19 | 2013-02-27 | Hoffmann La Roche | Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer. |
CA2805709A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
AR082693A1 (es) | 2010-08-17 | 2012-12-26 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf |
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
CA2817583A1 (en) | 2010-11-15 | 2012-05-24 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
CA2823044C (en) * | 2010-12-31 | 2022-08-16 | Jay M. Short | Express humanization of antibodies |
CN103502271B (zh) | 2011-02-28 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 抗原结合蛋白 |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
ES2692268T3 (es) | 2011-03-29 | 2018-12-03 | Roche Glycart Ag | Variantes de Fc de anticuerpo |
CN103857395A (zh) | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Akt抑制剂化合物和阿比特龙的组合及使用方法 |
CN108178789B (zh) | 2011-04-20 | 2021-11-02 | 阿塞勒隆制药公司 | 内皮糖蛋白多肽及其用途 |
US20140178398A1 (en) | 2011-05-03 | 2014-06-26 | Genentech, Inc | Vascular disruption agents and uses thereof |
WO2012172054A1 (en) | 2011-06-16 | 2012-12-20 | Scil Proteins Gmbh | Modified multimeric ubiquitin proteins binding vegf-a |
US9057728B2 (en) | 2011-07-12 | 2015-06-16 | Epitomics, Inc. | FACS-based method for obtaining an antibody sequence |
CN103890008A (zh) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 在顽固性肿瘤中抑制血管发生 |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
EA201400996A1 (ru) | 2012-03-13 | 2015-03-31 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия для лечения рака яичника |
AU2013267267B2 (en) | 2012-05-31 | 2017-10-26 | Genentech, Inc. | Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
BR112014032193A2 (pt) | 2012-06-27 | 2017-06-27 | Hoffmann La Roche | métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
AU2013299724A1 (en) | 2012-08-07 | 2015-02-26 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
CA2890906A1 (en) | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
FR2998579B1 (fr) | 2012-11-27 | 2015-06-19 | Commissariat Energie Atomique | Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
CA2906057A1 (en) | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Antibody formulations |
AU2014249243C1 (en) | 2013-03-13 | 2019-08-08 | Imaginab, Inc. | Antigen binding constructs to CD8 |
JP2016524611A (ja) | 2013-05-23 | 2016-08-18 | ファイヴ プライム セラピューティクス インク | がんを治療する方法 |
CN104341504B (zh) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
JP6422956B2 (ja) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
EP3851118A1 (en) | 2013-10-25 | 2021-07-21 | Acceleron Pharma Inc. | Endoglin peptides to treat fibrotic diseases |
ES2875878T3 (es) | 2013-11-18 | 2021-11-11 | Formycon Ag | Composición farmacéutica de un anticuerpo anti-VEGF |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
PT3081576T (pt) * | 2013-12-12 | 2019-10-15 | Jiangsu Hengrui Medicine Co | Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo |
CR20160270A (es) | 2013-12-20 | 2016-09-05 | Hoffmann La Roche | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CR20160425A (es) | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
SG11201608106PA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
WO2015173260A1 (en) | 2014-05-12 | 2015-11-19 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
KR102486180B1 (ko) | 2014-06-06 | 2023-01-11 | 레드우드 바이오사이언스 인코포레이티드 | 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
JP2017523776A (ja) | 2014-07-14 | 2017-08-24 | ジェネンテック, インコーポレイテッド | 膠芽腫の診断方法及びその治療用組成物 |
US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
CA3133162C (en) | 2014-08-12 | 2024-02-13 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
BR112017004393A2 (pt) | 2014-09-15 | 2018-02-27 | Genentech Inc | formulações de anticorpo |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
ES2952717T3 (es) | 2014-10-14 | 2023-11-03 | Novartis Ag | Moléculas de anticuerpos contra PD-L1 y usos de las mismas |
CA2959821A1 (en) | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
TWI705976B (zh) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体 |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
CA2968359A1 (en) | 2014-12-23 | 2016-06-30 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
CN113929779A (zh) * | 2015-06-24 | 2022-01-14 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
KR20180050321A (ko) | 2015-08-07 | 2018-05-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
MA43113B1 (fr) | 2015-10-30 | 2021-06-30 | Hoffmann La Roche | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
WO2017079419A1 (en) | 2015-11-05 | 2017-05-11 | The Regents Of The University Of California | Cells labelled with lipid conjugates and methods of use thereof |
MX2018006171A (es) | 2015-11-18 | 2018-12-19 | Formycon Ag | Jeringa de plastico precargada que contiene un antagonista de vegf. |
CN108883057A (zh) | 2015-11-18 | 2018-11-23 | Sio2医药产品公司 | 用于眼科配制品的药物包装 |
RU2734958C2 (ru) | 2015-11-18 | 2020-10-26 | Формикон Аг | Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf |
EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CA3011638C (en) | 2016-01-26 | 2023-01-10 | Formycon Ag | Liquid formulation of a vegf antagonist |
CN105481981B (zh) * | 2016-01-27 | 2019-03-19 | 中国人民解放军第二军医大学 | 靶向vegf双特异性抗体及其用途 |
MX2018012492A (es) | 2016-04-15 | 2019-06-06 | Genentech Inc | Métodos para monitorear y tratar el cáncer. |
CN109154027A (zh) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
CN109690315A (zh) | 2016-07-08 | 2019-04-26 | 豪夫迈·罗氏有限公司 | 人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途 |
WO2018009939A1 (en) | 2016-07-08 | 2018-01-11 | Genentech, Inc. | Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene. |
WO2018031865A1 (en) | 2016-08-12 | 2018-02-15 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
US10919958B2 (en) * | 2016-08-23 | 2021-02-16 | Medimmune Limited | Anti-VEGF-A antibodies and uses thereof |
US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
CA3049656A1 (en) | 2017-01-10 | 2018-07-19 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator |
KR20190134631A (ko) | 2017-03-01 | 2019-12-04 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
EP3630043A1 (en) | 2017-05-24 | 2020-04-08 | Formycon AG | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
CA3063995A1 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
CN111511400A (zh) | 2017-12-29 | 2020-08-07 | 豪夫迈·罗氏有限公司 | 抗vegf抗体及其使用方法 |
BR112020017382A2 (pt) | 2018-03-09 | 2021-01-26 | Agenus Inc. | anticorpos anti-cd73 e métodos de uso dos mesmos |
EP3782618A4 (en) | 2018-04-16 | 2022-01-26 | OnQuality Pharmaceuticals China Ltd. | METHOD OF PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY |
MA52777A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Agents de liaison psma et utilisations correspondantes |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
CN113196061A (zh) | 2018-10-18 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 肉瘤样肾癌的诊断和治疗方法 |
WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
US20220185875A1 (en) | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
CA3136888A1 (en) | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- psma/cd3 antibody |
EP3962947A2 (en) | 2019-05-03 | 2022-03-09 | F. Hoffmann-La Roche AG | Methods of treating cancer with an anti-pd-l1 antibody |
CN113795514A (zh) * | 2019-05-09 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 制备抗体的方法 |
AU2019461286B2 (en) | 2019-08-09 | 2024-01-04 | Anhui Biox Vision Biological Technology Co., Ltd. | Anti-VEGF-anti-PD1 bispecific antibody with new-type structure |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
CN113461824A (zh) | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
EP4127724A1 (en) | 2020-04-03 | 2023-02-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
FR3110838B1 (fr) | 2020-05-28 | 2022-06-24 | Commissariat Energie Atomique | Complexe immunomodulateur et ses applications pour la thérapie |
CA3182607A1 (en) | 2020-06-30 | 2022-01-06 | Erik Hans MANTING | Use of leukemia-derived cells in ovarian cancer vaccines |
CN114106190A (zh) | 2020-08-31 | 2022-03-01 | 普米斯生物技术(珠海)有限公司 | 一种抗vegf/pd-l1双特异性抗体及其用途 |
MX2023005529A (es) | 2020-11-13 | 2023-05-25 | Genentech Inc | Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos. |
JP2024506249A (ja) | 2021-01-22 | 2024-02-13 | メンドゥス・ベスローテン・フェンノートシャップ | 腫瘍ワクチン接種の方法 |
KR20230137393A (ko) | 2021-01-28 | 2023-10-04 | 얀센 바이오테크 인코포레이티드 | Psma 결합 단백질 및 이의 용도 |
AU2022235341A1 (en) | 2021-03-12 | 2023-09-21 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
EP4330436A1 (en) | 2021-04-30 | 2024-03-06 | Genentech, Inc. | Therapeutic and diagnostic methods and compositions for cancer |
WO2023279092A2 (en) | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
IL309120A (en) | 2021-07-28 | 2024-02-01 | Hoffmann La Roche | Methods and compositions for the treatment of cancer |
WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0397834B1 (en) * | 1988-10-28 | 2000-02-02 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2108147C (en) * | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
DK0590058T3 (da) * | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
CA2128862C (en) | 1992-02-11 | 2008-05-20 | Jonathan G. Seidman | Homogenotization of gene-targeting events |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
DE69233803D1 (de) * | 1992-10-28 | 2011-03-31 | Genentech Inc | Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
DE69434538T2 (de) * | 1994-03-08 | 2006-08-10 | Human Genome Sciences, Inc. | Vaskulärer endothelialer Wachstumsfaktor 2 |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
EP0971959B1 (en) * | 1997-04-07 | 2005-12-28 | Genentech, Inc. | Humanized antibodies and methods for forming humanized antibodies |
-
1998
- 1998-04-03 EP EP98918013A patent/EP0971959B1/en not_active Expired - Lifetime
- 1998-04-03 KR KR1019997009194A patent/KR100794454B1/ko not_active IP Right Cessation
- 1998-04-03 DE DE69832970T patent/DE69832970T2/de not_active Expired - Lifetime
- 1998-04-03 CN CN200910147016A patent/CN101838328A/zh active Pending
- 1998-04-03 ES ES06024703T patent/ES2349559T3/es not_active Expired - Lifetime
- 1998-04-03 DE DE69841815T patent/DE69841815D1/de not_active Expired - Lifetime
- 1998-04-03 PT PT98918013T patent/PT971959E/pt unknown
- 1998-04-03 AT AT98918013T patent/ATE314395T1/de active
- 1998-04-03 AT AT05077948T patent/ATE501170T1/de active
- 1998-04-03 PT PT10007444T patent/PT2301580E/pt unknown
- 1998-04-03 DK DK98918013T patent/DK0971959T3/da active
- 1998-04-03 AT AT06024703T patent/ATE476664T1/de active
- 1998-04-03 AT AT10007444T patent/ATE541586T1/de active
- 1998-04-03 EP EP10007444A patent/EP2301580B1/en not_active Expired - Lifetime
- 1998-04-03 EP EP10181127A patent/EP2336190A3/en not_active Withdrawn
- 1998-04-03 DK DK10007444.2T patent/DK2301580T3/da active
- 1998-04-03 DK DK06024703.8T patent/DK1787999T3/da active
- 1998-04-03 PT PT05077948T patent/PT1695985E/pt unknown
- 1998-04-03 KR KR1019997009193A patent/KR100856995B1/ko not_active IP Right Cessation
- 1998-04-03 CN CNB98805910XA patent/CN1191276C/zh not_active Expired - Lifetime
- 1998-04-03 SI SI9830930T patent/SI1695985T1/sl unknown
- 1998-04-03 PT PT98917991T patent/PT973804E/pt unknown
- 1998-04-03 SI SI9830876T patent/SI0973804T1/sl unknown
- 1998-04-03 DK DK05077948.7T patent/DK1695985T3/da active
- 1998-04-03 CN CN2007101971402A patent/CN101210050B/zh not_active Expired - Lifetime
- 1998-04-03 SI SI9830824T patent/SI0971959T1/sl unknown
- 1998-04-03 SI SI9830927T patent/SI1787999T1/sl unknown
- 1998-04-03 PT PT06024703T patent/PT1787999E/pt unknown
- 1998-04-03 AU AU71023/98A patent/AU740738B2/en not_active Expired
- 1998-04-03 BR BRPI9809388A patent/BRPI9809388B8/pt not_active IP Right Cessation
- 1998-04-03 EP EP10010132A patent/EP2338915A3/en not_active Withdrawn
- 1998-04-03 WO PCT/US1998/006724 patent/WO1998045332A2/en active IP Right Grant
- 1998-04-03 ES ES05077948T patent/ES2361267T3/es not_active Expired - Lifetime
- 1998-04-03 TR TR1999/02818T patent/TR199902818T2/xx unknown
- 1998-04-03 CN CN201410411945.2A patent/CN104231078A/zh active Pending
- 1998-04-03 NZ NZ500077A patent/NZ500077A/en not_active IP Right Cessation
- 1998-04-03 EP EP05077948A patent/EP1695985B1/en not_active Expired - Lifetime
- 1998-04-03 SI SI9830935T patent/SI2301580T1/sl unknown
- 1998-04-03 ES ES10007444T patent/ES2380575T3/es not_active Expired - Lifetime
- 1998-04-03 CN CN2007101971417A patent/CN101210051B/zh not_active Expired - Lifetime
- 1998-04-03 EP EP16181733.3A patent/EP3260468A1/en not_active Withdrawn
- 1998-04-03 CN CN2009101470179A patent/CN101665536B/zh not_active Expired - Lifetime
- 1998-04-03 DE DE69842174T patent/DE69842174D1/de not_active Expired - Lifetime
- 1998-04-03 CA CA2286397A patent/CA2286397C/en not_active Expired - Lifetime
- 1998-04-03 IL IL13223998A patent/IL132239A0/xx not_active IP Right Cessation
- 1998-04-03 ES ES98918013T patent/ES2256935T3/es not_active Expired - Lifetime
- 1998-04-03 JP JP54296498A patent/JP4191258B2/ja not_active Expired - Lifetime
- 1998-04-06 ZA ZA982907A patent/ZA982907B/xx unknown
- 1998-04-06 ZA ZA982908A patent/ZA982908B/xx unknown
-
1999
- 1999-10-06 IL IL132240A patent/IL132240A/en not_active IP Right Cessation
- 1999-10-06 NO NO19994870A patent/NO325823B1/no not_active IP Right Cessation
-
2000
- 2000-07-17 HK HK00104355A patent/HK1025338A1/xx not_active IP Right Cessation
-
2006
- 2006-05-24 IL IL175906A patent/IL175906A/en not_active IP Right Cessation
-
2007
- 2007-01-12 HK HK07100445.4A patent/HK1095334A1/xx not_active IP Right Cessation
- 2007-04-04 LT LTPA2007004C patent/LTC0973804I2/lt unknown
-
2008
- 2008-09-09 HK HK08109991.2A patent/HK1114621A1/xx not_active IP Right Cessation
- 2008-09-09 HK HK08109992.1A patent/HK1114622A1/xx not_active IP Right Cessation
-
2010
- 2010-06-25 HK HK10106257.3A patent/HK1139425A1/xx not_active IP Right Cessation
- 2010-10-12 CY CY20101100908T patent/CY1111345T1/el unknown
-
2011
- 2011-04-15 HK HK11103803.8A patent/HK1149501A1/xx not_active IP Right Cessation
- 2011-06-02 CY CY20111100536T patent/CY1111520T1/el unknown
-
2012
- 2012-03-29 CY CY20121100322T patent/CY1112757T1/el unknown
-
2015
- 2015-05-21 HK HK15104841.6A patent/HK1204329A1/xx unknown
-
2017
- 2017-08-01 NO NO2017039C patent/NO2017039I2/no unknown
-
2019
- 2019-12-11 NO NO2019045C patent/NO2019045I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO325823B1 (no) | Humaniserte antistoffer, fremgangsmate for a fremstille humaniserte antistoffer og anvendelsen av slike. | |
DE60025015T2 (de) | Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose | |
JP4753578B2 (ja) | 合成抗体ファージライブラリー | |
JP6093715B2 (ja) | 免疫グロブリンドメインの工学的作製 | |
US7785903B2 (en) | Variable domain library and uses | |
CA2562604C (en) | Preparation of scfv antibody fragments | |
CA2909921C (en) | Synthetic library of specific binding molecules | |
US20050079574A1 (en) | Synthetic antibody phage libraries | |
AU2006329208B2 (en) | Methods for generating and screening fusion protein libraries and uses thereof | |
JP2012505654A (ja) | 抗体をヒト化及び親和性成熟する方法 | |
JPH06510671A (ja) | キメラ抗体の製造−組合せアプローチ | |
JP2001509817A (ja) | 抗vegf抗体 | |
KR102637804B1 (ko) | 개과 항체 라이브러리 | |
KR20160087766A (ko) | 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리 | |
EP2305710A2 (en) | Synthetic antibody phage libraries | |
AU2010322202A1 (en) | Display of disulfide linked dimeric proteins on filamentous phage | |
KR20220026869A (ko) | 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리 | |
Vellalore Maruthachalam | NEXT-GENERATION SEQUENCING AND MOTIF GRAFTING APPLICATIONS IN SYNTHETIC ANTIBODY DISCOVERY | |
CN118043079A (zh) | 免疫缀合物分子及其相关方法和组合物 | |
WO2022129524A1 (en) | Fast-track humanisation of specific binding molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |